Johnson & Johnson (JNJ) Acquires Shockwave Medical (SWAV) for $13.1B

By Patricia Miller


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

J&J acquires Shockwave Medical for $13.1B, bolstering its medical device portfolio and positioning retail investors for potential growth in the cardiovascular technology sector.

heart health clipart image, designed in a wide format to emphasize the importance of cardiovascular wellness through lifestyle choices.
JNJ to Expand Heart Disease Treatment Portfolio

What You Need To Know

Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical Inc (NASDAQ: SWAV) for $13.1 billion to expand its medical device offerings for heart disease treatment. The deal is expected to close by mid-year. With recent acquisitions in medical technology, J&J aims to become a leader in cardiovascular technology. Shockwave's intravascular lithotripsy technology, which uses sound waves to break up calcification in heart vessels, will enhance J&J's product portfolio.

The acquisition has generated interest from companies like Boston Scientific (NYSE: BSX). J&J will fund the deal with cash and debt. It is expected to slightly dilute J&J's shares in the short term. This acquisition is part of J&J's strategy to build its medical technology and drug development portfolio in preparation for the upcoming loss of exclusivity for its top-selling drug, Stelara. JPMorgan Securities and Perella Weinberg Partners are advising J&J and Shockwave, respectively.

Sign up for Investing Intel Newsletter

Why This Is Important for Retail Investors

  1. Diversification of J&J's Portfolio: The acquisition of Shockwave Medical allows Johnson & Johnson to expand its offerings in the medical device market, providing retail investors with exposure to an additional sector within the healthcare industry. This diversification can help mitigate risk and potentially enhance overall portfolio performance.

  2. Potential Revenue Growth: With J&J's strategic acquisition of Shockwave, retail investors have the opportunity to benefit from the potential revenue growth that may result from the expansion of the company's cardiovascular technology portfolio. As Shockwave's technology gains traction in the market, it could drive increased sales and potentially boost J&J's financial performance.

  3. Competitive Advantage in a Growing Market: By becoming a leader in four rapidly growing cardiovascular technology categories, JNJ gains a competitive advantage. This is important for retail investors as it positions the company to capitalize on the expanding demand for treatments related to heart disease. Being at the forefront of innovation in this field can drive long-term profitability.

  4. Favorable Market Conditions: The growing interest in cardiovascular technology and the potential for further advancements in the field provide favorable market conditions for J&J's investment in Shockwave Medical. This can create opportunities for retail investors to benefit from potential capital appreciation as the market responds to the company's strategic moves.

  5. Forward-thinking Strategy: J&J's continuous efforts to enhance its medical technology and drug development portfolio demonstrate a forward-thinking strategy. This strategic approach to remain competitive and adapt to changing market dynamics can instill confidence in retail investors, signaling the company's commitment to long-term growth and value creation.

How Can You Use This Information?

Here are some of the investing ideas that can be explored using this information:

Growth Investing

Given J&J's strategic acquisitions and expansions in the medical technology sector, there may be potential for growth in the company's cardiovascular technology portfolio. Investors with a growth investing approach might be interested in considering JNJ stock as a potential investment opportunity.

Growth investing focuses on stocks of companies expected to grow at an above-average rate compared to other stocks in the market; learn more in our article titled 'What is Growth Investing?'.

Defensive investing

With J&J's focus on medical technology and expanding its product portfolio, including treatments for heart disease, it positions the company as a defensive investment option. Investors seeking stability and resilience in uncertain market conditions may find J&J's defensive qualities appealing.

Defensive Investing focuses on securing a portfolio by choosing companies that are less sensitive to economic downturns.

Thematic Investing

J&J's acquisition of Shockwave Medical aligns with the theme of advancements in cardiovascular technology. Investors interested in thematic investing focused on healthcare innovations and technological advancements may find J&J's move worth exploring.

Thematic Investing selects assets based on projected trends or themes believed to offer growth opportunities.

Read What Others Are Saying

Reuters: J&J boosts heart device business with $12.5 bln Shockwave Medical deal

FT: Live news: Johnson & Johnson buys device maker Shockwave for $13bn

Sign up for Investing Intel Newsletter

What you should read next:

Popular ETFs

Some investors prefer to invest in stocks via an exchange-traded fund for ease and reduced risk. Some popular ETFs include the following:

  • Large-Caps: Vanguard Mega Cap ETF (MGC)

  • Mid-Caps: Vanguard Mid-Cap ETF (VO)

  • Small-Caps: Vanguard Small-Cap ETF (VB)

  • Growth: iShares Core S&P U.S. Growth ETF (IUSG)

  • Value: iShares Core S&P US Value ETF (IUSV)

  • Emerging Markets: Vanguard FTSE Emerging Markets ETF (VWO)

  • Developed Markets: Vanguard FTSE Developed Markets ETF (VEA)

  • Agg Bonds: iShares Core U.S. Aggregate Bond ETF (AGG) - This ETF provides broad exposure to U.S. investment-grade bonds.

  • TIPS: iShares TIPS Bond ETF (TIP) - This ETF offers exposure to U.S. Treasury Inflation-Protected Securities (TIPS). TIPS are government bonds specifically designed to help protect against inflation.

  • REITs: Vanguard Real Estate ETF (VNQ)

  • Commodities: iShares S&P GSCI Commodity Indexed Trust (GSG)

  • Energy: Energy Select Sector SPDR Fund (XLE)

  • Clean Energy: Invesco Winderhill Clean Energy ETF (PBW)

  • Obesity and Heart Disease: Tema Cardiovascular and Metabolic ETF (HRTS)

Explore more on these topics:



This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter